Investigating genetic markers and antibody responses to predict chronic graft-versus-host disease
Official title: IGHG Genes (GM Allotypes) and Anti-CMV (UL70) Antibody Responses as Prognostic Markers for Chronic Graft-Versus-Host-Disease
Funded at Medical University of South Carolina · NIH-10809751 · Data updated 2026-11-12
This study is looking for clues in your genes and immune responses that might help doctors predict if you'll develop chronic graft-versus-host disease after a stem cell transplant, so if you join, you may have some tests done to help us learn more about this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | April 1, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $113,250 |
| NIH project number | 5R21HL167662-02 |
| Project ID | NIH-10809751 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are undergoing or have undergone hematopoietic cell transplantation.
✕Less likely to help
Patients who have not received a hematopoietic cell transplant or those without a history of chronic graft-versus-host disease may not benefit from this research.
What this research studies
This research focuses on identifying genetic markers and antibody responses that could help predict the onset of chronic graft-versus-host disease (cGVHD) in patients who have undergone hematopoietic cell transplantation (HCT). By examining immunoglobulin GM genes and their relationship with cytomegalovirus (CMV) infections, the study aims to uncover biomarkers that can indicate which patients are at higher risk for developing cGVHD. The approach involves analyzing the interaction between GM alleles and antibody responses to CMV, which may influence the immune response and disease progression. Patients participating in this research may undergo genetic testing and antibody assessments to contribute to the understanding of cGVHD risk factors.
Why it matters
Potential benefit: If successful, this research could lead to improved early identification of patients at risk for chronic graft-versus-host disease, allowing for timely interventions.
How similar studies have gone: Other research has shown promise in identifying genetic markers for various autoimmune conditions, suggesting that this approach may yield valuable insights for cGVHD as well.
Where this research is happening
-
Medical University of South Carolina
Charleston, United States Active
Researchers
- Principal investigator: Pandey, Janardan P — Medical University of South Carolina
- Study coordinator: Pandey, Janardan P
Related research
Other NIH-funded projects on the same topics.
-
Targeting early oral GVHD to improve mouth health after stem cell transplant
A study at UW–Madison will explore why some transplant patients develop painful oral GVHD and test ideas to prevent and lessen mouth-related problems.
-
Microbiome-based therapy for treatment-refractory GVHD after stem cell transplant
A microbiome-based therapy is being developed to help people who have graft-versus-host disease that doesn’t respond to standard treatments after a stem cell transplant.
-
Role of altered mitochondria in preventing GVHD after stem cell transplant
This NIH grant explores how damaged mitochondria released during pre-transplant conditioning may trigger graft-versus-host disease and tests ways to fix mitochondrial dynamics to prevent GVHD.
-
Fecal transplant plus fiber to treat graft-versus-host disease after blood stem cell transplant
A study to see if giving fecal transplant along with dietary fiber helps gut health and reduces complications in patients who have received a stem cell transplant and developed graft-versus-host disease.
-
Using medium-chain fatty acids and a fat-sensing receptor to treat chronic graft-versus-host disease
This project looks at whether changing medium‑chain fatty acids or blocking a fat sensor called GPR84 can help people with chronic graft‑versus‑host disease after a bone marrow/stem cell transplant.
-
Microbiome-based oral therapy for gut GVHD after stem cell transplant
Researchers are testing an oral live Biotherapeutic Product to help the gut microbiome improve graft-versus-host disease after stem cell transplant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.